Biogen has acquired the rights to use InnoCare Pharma's Orelabrutinib to treat multiple sclerosis and autoimmune diseases outside of China. The potential drug is currently in Phase 2 trials. As part of the deal, InnoCare will receive an upfront payment of $125 million from Biogen, as well as the right to receive an additional $812.5 million when certain milestones for the drug are reached.
Biogen has acquired the rights to use InnoCare Pharma's Orelabrutinib to treat multiple sclerosis and autoimmune diseases outside of China. The potential drug is currently in Phase 2 trials. As part of the deal, InnoCare will receive an upfront payment of $125 million from Biogen, as well as the right to receive an additional $812.5 million when certain milestones for the drug are reached. 
investors.biogen.com
English (US) 